Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06277466
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2024-02-05
Brief Title:
Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls
Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Organization:
The Affiliated Hospital of Xuzhou Medical University
Study Overview
Official Title:
Department of Pharmacy the Affiliated Hospital of Xuzhou Medical University
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression
Participants T2DM patients and controls were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes
Participants T2DM patients and controls were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes
Detailed Description:
The primary objective of this study was to investigate the changes of the expression of T2DM susceptible genes NOS1AP KCNQ1 TCF7L2 WSF1 GLP-1R etc in participants newly diagnosed T2DM patients and controls after gene mutation
Secondly the expression differences of T2DM susceptible genes in T2DM patients with different genotypes were compared and the relationship between the expression differences and clinicopathological characteristics of T2DM patients was analyzed
Participants newly diagnosed T2DM patients and healthy subjects were screened from the department of endocrinology and health management center whose fresh peripheral blood were collected The normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected in the department of general surgery The DNA genome was extracted for genotyping and then the expression levels of T2DM related susceptibility genes under different genotypes were detected by ELISA kits PCR WBHE staining IHC staining ect
The basic information of T2DM patients was collected including demographic characteristics physiological and biochemical dataThen investigators further compared the differences in the expression of susceptible genes between newly diagnosed T2DM patients and controls
Secondly the expression differences of T2DM susceptible genes in T2DM patients with different genotypes were compared and the relationship between the expression differences and clinicopathological characteristics of T2DM patients was analyzed
Participants newly diagnosed T2DM patients and healthy subjects were screened from the department of endocrinology and health management center whose fresh peripheral blood were collected The normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected in the department of general surgery The DNA genome was extracted for genotyping and then the expression levels of T2DM related susceptibility genes under different genotypes were detected by ELISA kits PCR WBHE staining IHC staining ect
The basic information of T2DM patients was collected including demographic characteristics physiological and biochemical dataThen investigators further compared the differences in the expression of susceptible genes between newly diagnosed T2DM patients and controls
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None